This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026. Myostatin inhibitors are being developed to treat conditions like muscular dystrophy and obesity. Notable candidates include Regeneron's trevogrumab and Eli Lilly's bimagrumab. Approval status can be verified through official regulatory agency announcements, such as those from the FDA (https://www.fda.gov/).